Vanguard Global Advisers
DNA icon

Vanguard Global Advisers’s Ginkgo Bioworks DNA Stock Holding History

Vanguard Global Advisers’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$156K Hold
15,732
– – ﹤0.01% 2598
2026
Q1 		$96.4K Buy
+15,732
New +$131K ﹤0.01% 2745

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Vanguard Global Advisers's DNA Position: Q2 2026 in Review

Vanguard Global Advisers held its Ginkgo Bioworks (DNA) position steady in Q2 2026 at 15,732 shares worth $156K. The position accounts for ﹤0.01% of the portfolio, ranked #2598.

Vanguard Global Advisers first reported a position in DNA in Q1 2026 and has held it in 2 quarters since. 182 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Vanguard Global Advisers held 15,732 shares of Ginkgo Bioworks worth $156K as of Q2 2026.
  • Vanguard Global Advisers left its Ginkgo Bioworks share count unchanged in Q2 2026.
  • Ginkgo Bioworks made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2598 holding.
  • Vanguard Global Advisers first reported a position in Ginkgo Bioworks in Q1 2026 and has held it in 2 quarters since.
  • 182 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.